KRKA, tovarna zdravil, d.d., Novo mesto financials
KRKA, tovarna zdravil, d.d., Novo mesto
Country: SI Reporting currency: EUR Latest annual report: 2024-12-31
LEI:
549300H9RLRTRTLRUZ73 Financial statements
(EUR, as reported — unscaled; 114 line items across 2 annual periods)
| Line item | 2024 | 2023 |
|---|---|---|
| Income statement | ||
| Revenue | €1.91B | €1.81B |
| Cost of sales | €815.7M | €779.7M |
| Gross profit | €1.09B | €1.03B |
| Other income | €7.1M | €6.1M |
| Operating profit (EBIT) | €427.6M | €399.6M |
| Net finance income / (cost) | -€8.5M | -€32.5M |
| Finance costs | €42.4M | €56.1M |
| Profit before tax | €419.1M | €367.1M |
| Income tax expense | €62.9M | €53.4M |
| Profit for the year | €356.2M | €313.7M |
| — attributable to owners | €357.0M | €313.9M |
| — attributable to NCI | -€784.0K | -€214.0K |
| Total comprehensive income | €312.0M | €260.2M |
| Per share | ||
| Basic EPS | €11.60 | €10.14 |
| Diluted EPS | €11.60 | €10.14 |
| Free cash flow / share | €8.24 | €3.14 |
| Cash flow statement | ||
| Net cash from operating activities | €360.9M | €227.3M |
| Net cash from investing activities | €75.1M | -€343.2M |
| Purchase of PP&E (capex) | €107.8M | €130.0M |
| Purchase of intangibles | €7.6M | €9.2M |
| Net cash from financing activities | -€264.5M | -€229.8M |
| Dividends paid | €230.9M | €204.4M |
| Lease liability payments | €4.2M | €4.2M |
| Net change in cash | €171.5M | -€345.8M |
| Balance sheet | ||
| Total assets | €2.85B | €2.76B |
| Non-current assets | €1.02B | €1.06B |
| Property, plant & equipment | €806.6M | €790.3M |
| Intangible assets & goodwill | €100.7M | €102.3M |
| Current assets | €1.83B | €1.71B |
| Inventories | €638.6M | €604.6M |
| Trade & other receivables | €552.7M | €509.1M |
| Cash & equivalents | €344.9M | €174.0M |
| Total equity | €2.24B | €2.18B |
| — attributable to owners | €2.22B | €2.16B |
| Non-controlling interests | €19.6M | €19.7M |
| Non-current liabilities | €162.7M | €149.2M |
| Lease liabilities (non-current) | €9.5M | €8.5M |
| Current liabilities | €448.6M | €433.3M |
| Lease liabilities (current) | €3.6M | €3.5M |
| Deferred tax liabilities | €10.6M | €10.7M |
| Derived metrics | ||
| Free cash flow | €253.2M | €97.2M |
| Operating margin | 22.4% | 22.1% |
| Net margin | 18.7% | 17.4% |
| Return on equity | 15.9% | 14.4% |
| Cash conversion ratio | 1.01× | 0.72× |
| Capex coverage | 3.35× | 1.75× |
| Other reported items | ||
| Adjustments For Decrease Increase In Inventories | -€52.8M | -€62.7M |
| Adjustments For Decrease Increase In Trade Account Receivable | -€41.6M | -€104.1M |
| Adjustments For Decrease Increase In Trade and Other Receivables | -€2.2M | -€3.7M |
| Adjustments For Depreciation and Amortisation Expense | €92.5M | €104.6M |
| Adjustments For Finance Costs | €9.5M | €13.0M |
| Adjustments For Finance Income | €31.0K | €4.0K |
| Adjustments For Income Tax Expense | €62.9M | €53.4M |
| Adjustments For Increase Decrease In Deferred Income Other Than Contract Liabilities | €107.0K | -€501.0K |
| Adjustments For Increase Decrease In Other Current Liabilities | €3.9M | €15.9M |
| Adjustments For Increase Decrease In Trade Account Payable | -€3.3M | €24.5M |
| Adjustments For Provisions | -€451.0K | €1.8M |
| Adjustments For Unrealised Foreign Exchange Losses Gains | -€18.8M | -€27.0M |
| Adjustments To Reconcile Profit Loss Other Than Changes In Working Capital | €133.5M | €132.8M |
| Cash Advances and Loans Made To Other Parties Classified As Investing Activities | €3.5M | €2.0M |
| Cash Flows From Used In Operations Before Changes In Working Capital | €489.7M | €446.5M |
| Cash Receipts From Repayment of Advances and Loans Made To Other Parties Classified As Investing Activities | €31.2M | €4.2M |
| Comprehensive Income Attributable To Noncontrolling Interests | -€110.0K | -€1.5M |
| Comprehensive Income Attributable To Owners of Parent | €312.1M | €261.7M |
| Current Contract Assets | €672.0K | €429.0K |
| Current Contract Liabilities | €166.1M | €162.2M |
| Current Investments | €249.8M | €306.8M |
| Current Tax Liabilities Current | €24.4M | €9.0M |
| Deferred Tax Assets | €54.4M | €47.7M |
| Dividends Received Classified As Investing Activities | €941.0K | €798.0K |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | -€595.0K | €880.0K |
| Equity and Liabilities | €2.85B | €2.76B |
| Finance Income | €33.9M | €23.6M |
| General and Administrative Expense | €115.2M | €106.8M |
| Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss Trade Receivables | €2.2M | €3.7M |
| Income Tax Relating To Components of Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss | -€704.0K | €2.7M |
| Income Taxes Paid Refund Classified As Operating Activities | €34.6M | €94.1M |
| Increase Decrease Through Appropriation of Retained Earnings | €0 | €0 |
| Increase Decrease Through Changes In Ownership Interests In Subsidiaries That Do Not Result In Loss of Control | €0 | €1.3M |
| Increase Decrease Through Transactions With Owners | -€255.9M | -€217.0M |
| Interest Paid Classified As Financing Activities | €4.5M | €8.7M |
| Interest Received Classified As Investing Activities | €14.3M | €9.7M |
| Investments In Joint Ventures Accounted For Using Equity Method | €2.5M | €0 |
| Issued Capital | €54.7M | €54.7M |
| Liabilities | €611.2M | €582.5M |
| Noncurrent Assets Or Disposal Groups Classified As Held For Sale | €44.0K | €41.0K |
| Noncurrent Deferred Income Other Than Noncurrent Contract Liabilities | €5.7M | €5.5M |
| Noncurrent Investments In Equity Instruments Designated At Fair Value Through Other Comprehensive Income | €22.0M | €47.7M |
| Noncurrent Provisions | €136.9M | €124.4M |
| Other Cash Payments To Acquire Interests In Joint Ventures Classified As Investing Activities | €2.5M | €0 |
| Other Comprehensive Income | -€44.2M | -€53.5M |
| Other Comprehensive Income Before Tax Gains Losses On Remeasurements of Defined Benefit Plans | -€8.4M | -€12.0M |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | -€31.6M | -€49.7M |
| Other Comprehensive Income Net of Tax Financial Assets Measured At Fair Value Through Other Comprehensive Income | -€4.9M | €10.9M |
| Other Comprehensive Income That Will Be Reclassified To Profit Or Loss Net of Tax | -€31.6M | -€49.7M |
| Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss Net of Tax | -€12.6M | -€3.8M |
| Other Current Liabilities | €106.2M | €105.0M |
| Other Current Receivables | €28.9M | €51.4M |
| Other Noncurrent Assets | €1.2M | €1.1M |
| Other Reserves | €136.3M | €154.5M |
| Other Revenue | €3.5M | €4.5M |
| Payments To Acquire Or Redeem Entitys Shares | €25.0M | €13.9M |
| Proceeds From Contributions of Noncontrolling Interests | €0 | €1.3M |
| Proceeds From Sales of Investments Other Than Investments Accounted For Using Equity Method | €71.2M | €33.3M |
| Proceeds From Sales of Property Plant and Equipment Classified As Investing Activities | €1.6M | €2.4M |
| Proceeds From Sales Or Maturity of Financial Instruments Classified As Investing Activities | €2.0M | €4.3M |
| Purchase of Financial Instruments Classified As Investing Activities | €1.7M | €389.0K |
| Purchase of Investments Other Than Investments Accounted For Using Equity Method | €184.0K | €51.0K |
| Purchase of Treasury Shares | €25.0M | €13.9M |
| Research and Development Expense | €184.9M | €178.6M |
| Retained Earnings | €2.19B | €2.09B |
| Revenue From Contracts With Customers | €1.91B | €1.80B |
| Trade and Other Current Payables To Trade Suppliers | €148.3M | €153.8M |
| Treasury Shares | €163.5M | €138.5M |
Methodology
Every line item above is a fact tagged in KRKA, tovarna zdravil, d.d., Novo mesto's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.